Impact of Emerging Markets in Global Pharma 2013 and role of Top 12 Pharma
9
Pharmaceutical Emerging Markets Impact on Global Pharmaceutical Market 2012-2013 Emergpharma Pannel Preliminary Results More information: www.emergpharma.com
-
Upload
jose-ignacio-diaz -
Category
Healthcare
-
view
885 -
download
2
description
Global Pharmaceutical market grew 2% in 2013 although Developed and Emerging Markets played a very different role: While EM delivered 30 bn USD of additional revenues, DM reduced sales more than 8 bn USD Within Developed Markets, EU dropped 16 bn USD (-7%) versus 2012 while USA, Canada, Japan and other APAC developed markets grew at an average of 2% In Emerging Markets, BRIC contributed more than 80% to growth, meaning 25 bn USD, while rest of Pharmerging represented nearly 5 additional billion Top 12 Pharmaceutical Companies represent 39% of Global Pharmaceutical Market in 2013 with much stronger position in Developed Markets (42,5%) than in Emerging Markets (27%) In 2013 MS of Top 12 declined in both market segments, but while in DM decrease was 0,8%, in EM nearly doubled (-1,5%) While more than 80% of Market Growth is delivered by Emerging Markets, Big Pharma is strongly losing MS on this Market Segment
Transcript of Impact of Emerging Markets in Global Pharma 2013 and role of Top 12 Pharma
Pharmaceutical Emerging MarketsImpact on Global Pharmaceutical Market 2012-2013 Emergpharma Pannel Preliminary Results
More information: www.emergpharma.com
Global Pharmaceutical Market2011-2013 (bn USD)
2012 2013 -
200.00
400.00
600.00
800.00
1,000.00
1,200.00
751.91 743.79
305.30 335.86
Developed Markets Emerging Markets
+2%
-1 %
+10%
Source: Emergpharma Pannel
Emerging Markets (bn USD)
2012 2013 -
50.00
100.00
150.00
200.00
250.00
300.00
350.00
152.44 178.42
152.86 157.44
BRIC Other Emerging
+3%
+17%
Source: Emergpharma Pannel
Developed Markets(bn USD)
2012 2013 -
100.00
200.00
300.00
400.00
500.00
600.00
700.00
800.00
239.54 223.50
512.37 520.29
EU Rest of Dev. Markets
-1%
+2%
-7%
Source: Emergpharma Pannel
Market Growth 2013 (bn USD by Segment)
Global Mark
et 2012
BRIC
Rest of E
merging
Developed M
arkets
Global Mark
et 2013
+25,3+4,6
-8,1
Source: Emergpharma Pannel
Top 12 Pharma in Global MarketNovartis, Pfizer, Merck, Sanofi, GSK, Roche, Astra, J&J, Abbvie,
Teva, Lilly and Boehringer Ingelheim
2012 2013 -
200.00
400.00
600.00
800.00
1,000.00
1,200.00
412.32 406.75
644.89 661.03
Top 12 Rest
+3%
-1%
Source: Emergpharma Pannel
Pharma Top 12 in Global, Developed and Emerging Markets
2012 201320.0%
25.0%
30.0%
35.0%
40.0%
45.0%
39.0% 38.1%
43.3% 42.5%
28.5%27.0%
MS Top 12 Global MS Top 12 Dev MarketsMS Top 12 Emerging Markets
Source: Emergpharma Pannel
Market Growth Drivers 2013
BRIC
Non European Dev M
arkets
Non BRIC Emerging M
arkets EU
25
84.6
-16
bn USD
Source: Emergpharma Pannel
Summary• Global Pharmaceutical market grew 2% in 2013 although Developed and
Emerging Markets played a very different role• While EM delivered 30 bn USD of additional revenues, DM reduced sales
more than 8 bn USD• Within Developed Markets, EU dropped 16 bn USD (-7%) versus 2012 while
USA, Canada, Japan and other APAC developed markets grew at an average of 2%
• In Emerging Markets, BRIC contributed more than 80% to growth, meaning 25 bn USD, while rest of Pharmerging represented nearly 5 additional billion
• Top 12 Pharmaceutical Companies represent 39% of Global Pharmaceutical Market in 2013 with much stronger position in Developed Markets (42,5%) than in Emerging Markets (27%)
• In 2013 MS of Top 12 declined in both market segments, but while in DM decrease was 0,8%, in EM nearly doubled (-1,5%)
• While more than 80% of Market Growth is delivered by Emerging Markets, Big Pharma is strongly losing MS on this Market Segment
Source: Emergpharma Pannel
